CASQ1 and Myalgia: Missense mutations in the muscle-specific SR Ca2+ buffer calsequestrin (CASQ1) have moreover been reported in patients with late-onset muscle weakness and myalgia, forming the mild end of the TAM/STRMK spectrum (Barone et al., 2017; Bohm et al., 2018; Figure 1).